Cisplatin, Etoposide, and Radiation Therapy in Treating Patients With Limited-Stage Small Cell Lung Cancer

• Status: Completed
• Trial end date: 2013-11-01
• Target enrollment: 0
• Participant gender: All

Summary

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage tumor cells. Combining more than one chemotherapy drug with radiation therapy may kill more tumor cells.

PURPOSE: This phase II trial is studying how well giving cisplatin and etoposide together with radiation therapy works in treating patients with limited-stage small cell lung cancer.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Radiation Therapy Oncology Group
• Collaborator: National Cancer Institute (NCI)
• Treatments: Cisplatin; Etoposide; Etoposide phosphate

Criteria

DISEASE CHARACTERISTICS:

• Histologically or cytologically confirmed small cell carcinoma of the lung by fine needle aspiration biopsy or two positive sputa

• Must have limited disease

• Stage I, II, IIIA, or IIIB

• Confined to 1 hemithorax, but excluding the following:

• T4 tumor based on malignant pleural effusion

• N3 disease based on contralateral hilar or contralateral supraclavicular involvement

• No pericardial or pleural effusions on chest x-ray (regardless of cytology)

• Measurable or evaluable disease

• Tumor must be able to be encompassed by limited radiotherapy fields without significantly compromising pulmonary function

• No prior complete tumor resection

PATIENT CHARACTERISTICS:

Age

• 18 to 100

Performance status

• Zubrod 0-1

Life expectancy

• Not specified

Hematopoietic

• Absolute granulocyte count at least 1,500/mm^3

• Platelet count at least 150,000/mm^3

Hepatic

• Bilirubin no greater than 1.5 mg/dL

Renal

• Creatinine no greater than 1.5 mg/dL

Cardiovascular

• No myocardial infarction within the past 6 months

• No symptomatic heart disease

Pulmonary

• No chronic obstructive pulmonary disease with Forced Expiratory Volume (FEV)-1 no greater than 0.8 liter

• No uncontrolled bronchospasm in the unaffected lung

Other

• Not pregnant or nursing

• Negative pregnancy test

• Fertile patients must use effective contraception

• Available for follow-up

• No other malignancy within the past 2 years except curatively treated basal cell or squamous cell skin cancer or non-invasive in situ malignancies

• No other concurrent serious medical illness

• No uncontrolled psychiatric illness

• No chronic alcohol or drug abuse

PRIOR CONCURRENT THERAPY:

Biologic therapy

• Not specified

Chemotherapy

• No prior chemotherapy

Endocrine therapy

• Not specified

Radiotherapy

• No prior radiotherapy to the chest or other area containing a large amount of bone marrow (e.g., more than 75% of pelvic bone)

Surgery

• See Disease Characteristics